Clintec International announced as SCRIP Awards 2013 finalist in the category of ‘Best CRO’ in recognition of continued corporate success.
Clintec International, the global Clinical Research Organisation has been named as a finalist for the accolade of ‘Best CRO’ at the SCRIP Awards 2013, to be held in London’s Lancaster Hotel on November 21st, 2013. Being on the final shortlist for this accolade, at what is one of the biggest ceremonies in the pharmaceutical industry, marks a further landmark in what has been a successful year for the company. 2013 has seen Clintec International launch, and enrol, students from fifteen countries into its innovative ‘Masters in International Clinical Research and Technology’ degree, an academic course run in conjunction with Edinburgh Napier University.
Furthermore, the year has seen the company enhance its worldwide clinical operations, with a new office opening in Turkey, an expansion of operations in Russia and South Africa, as well as making further strides in the burgeoning Middle East and North Africa (MENA) market. Success was also marked by owner and founder, Dr. Rabinder Buttar, winning the accolade of ‘Female Entrepreneur of the Year’ at the 2013 Scottish Business Awards, the largest business awards ceremony in the UK and one attended by ex-US President, Bill Clinton.
Commenting on the news of Clintec’s place on the final shortlist, and reflecting on her company’s achievements so far this year, Dr Buttar said; “I am delighted to see Clintec International once again being named as a finalist at the SCRIP Awards. Indeed, to be placed in the category of Best CRO, alongside a prestigious array of other commercial organisations, highlights the industry recognition that we enjoy for all the clinical work that we carry out for pharma and biotech companies on a daily basis. We are proud to count all of the world’s top five pharma companies amongst our growing client list, and we hope to continue enjoying a tremendously fruitful working relationship with all of our clients the world over. 2013 has been another highly successful growth year for our company, with our clinical operations expanding into new countries and territories, and the rolling out of our MSc programme. I am confident that we will continue forward in a similar vein as we head into the final quarter.”
She added: “with the company scheduled to appear at the Outsourcing Clinical Trials Conferences in San Diego and Boston respectively at the end of the month, we are set to further build and increase our 2013 presence in the markets with strong exposure to international life science and pharmaceutical companies.”
For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 203 6740 0r e-mail [email protected].
If you would like further information on Clintec International, Dr Rabinder Buttar, or our new MSc in International Clinical Research and Technology, please contact:
Bobby Bal, Senior Director, Corporate Development,
Glasgow, Scotland, UK.
Phone: +44 (0)141 226 1120
Fax: +44 (0)141 248 8993
Email: [email protected]
NOTES TO EDITORS
About Clintec International
Clintec is a global contract clinical research organisation, established in 1997 by Dr Rabinder Buttar, the company’s President and CEO. Clintec has a presence in over 40 developed and emerging countries, covering Western Europe, Central & Eastern Europe, the Middle East and North Africa, Central and South Africa, Latin America, India and the US.
In addition to Clintec’s vast expertise in oncology, the organisation has also conducted over 300 clinical trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. Clintec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world-class project managers and clinical research associates. Clintec’s fast, flexible and focused approach to clinical research ensures an added advantage to the drug development process.